pharmaphorum

JANUARY 29, 2023

What do I mean by vital acceleration? With the population ageing, the need for healthcare is growing fast: between 2015 and 2050, the proportion of the world’s population over 60 years old will nearly double from 12% to 22%, according to the World Health Organization. Keeping our elderly population healthy will prove a major challenge in years to come.

Nursing Homes 98

Nursing Homes Hospitals Vaccines 98

Hospital Pharmacy Europe

JANUARY 29, 2023

Bexotegrast in patients with idiopathic pulmonary fibrosis has been shown to produce a significant improvement in forced vital capacity In press release by the manufacturer, Pilant Therapeutics , interim data from a Phase IIa randomised, placebo-controlled trial, showed that bexotegrast at a daily dose of 320mg, achieved a statistically significant mean increase in forced vital capacity (FVC) after 12 weeks in patients with idiopathic pulmonary fibrosis.

Hospitals 95

Hospitals 95

STAT

JANUARY 29, 2023

The 7 a.m. Acela out of South Station in Boston trembled along the rails toward Manhattan. David Sabatini sat alone on the left side of the train. He had brought along a science paper to work on, but had a lot on his mind. He kept his Wordle streak alive on his phone, and stared out at the picturesque Connecticut coastline. His clothing hung loose from recent weight loss,   presumably   from stress.

100

100

Hospital Pharmacy Europe

JANUARY 29, 2023

CTX-009 when combined with paclitaxel improved the overall response rate for patients with advanced, metastatic biliary tract cancer according to findings presented at the 2023 ASCO Gastrointestinal Cancer Symposium in San Francisco. CTX-009 is a novel, bispecific antibody which causes blockade of delta-like ligand 4 Notch-1 signalling, inhibiting tumour growth as well as an blocking vascular endothelial growth factors (VEGF), that are recognised as important factors in tumour biology with a rol

Labelling 94

Labelling Hospitals 94

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Guardian - Pharmaceutical Industry

JANUARY 29, 2023

Patients are struggling to obtain essential medications after an early-pandemic healthcare transformation When the last tablet of Ritalin rattled softly in the plastic vial, Faati knew that sound meant trouble. The last time, they had run out of ADHD meds for three months and struggled to remember tasks or even tell time at the Washington state cafeteria where they worked.

86

86

Pharmaceutical Technology

JANUARY 29, 2023

The National Medical Products Administration (NMPA) of China has granted conditional approval for two domestically developed oral drugs to treat Covid-19. Simcere Pharmaceutical Group and Shanghai Junshi Biosciences’ subsidiary have submitted the applications for the two drugs Xiannuoxin (SIM0417) and VV116, respectively. The anti-SARS-CoV-2 drug candidate Xiannuoxin has been co-developed by Simcere Group, along with Shanghai Institute of Materia Medica (SIMM) and Wuhan Institute of Virology (WI

64

64

The FDA Law Blog

JANUARY 29, 2023

By Douglas B. Farquhar & Aisha T. Evans* — A recent analysis of statistics on FDA’s website, prepared for a presentation at a good manufacturing practices (GMP) conference in San Diego next week, shows a dramatic increase in the percentage of FDA drug manufacturing facility inspections that result in an “Official Action Indicated” classification.

FDA 59

FDA 59

pharmaphorum

JANUARY 29, 2023

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the class. The accelerated approval covers adults MCL patients who have previously been treated with at least two lines of systemic therapy, including a covalent BTK inhibitor.

FDA 59

FDA Labelling 59

BuzzRx

JANUARY 29, 2023

Sudafed is a brand-name medicine that contains the active ingredient pseudoephedrine. It is very effective in relieving nasal and sinus congestion. You don’t need a prescription to purchase this medicine; however, Sudafed products are kept behind the counter. To make a purchase, you must be at least 18 years old with a valid form of photo ID. Keeping Sudafed products behind the counter, along with other regulations, was mandated by the FDA in 2006 because pseudoephedrine, the main ingredient in

Dosage 52

Dosage Labelling Packaging Mayo Clinic 52

Med Ed 101

JANUARY 29, 2023

Tardive dyskinesia (TD) is a movement disorder that can cause repetitive, uncontrolled muscle movements in the face, neck, arms, and legs. In this article, we provide an update on tardive dyskinesia therapies. Symptoms of TD can include a mixture of orofacial dyskinesia, athetosis, dystonia, chorea, and tics. Symptoms are most commonly observed involving the mouth […] The post Tardive Dyskinesia Therapies appeared first on Med Ed 101.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

BuzzRx

JANUARY 29, 2023

Influenza or “flu” is a common infectious viral illness that affects millions of Americans each year. It is especially common during the winter months or flu season. You can catch the flu multiple times because the viruses keep changing (mutating) and your body does not have immunity to the newer versions. In most people, the flu is a short-lived, self-limited illness, but some people are at a high risk of developing flu complications.

Vaccines 52

Vaccines Immunization Chemotherapy 52

pharmaphorum

JANUARY 29, 2023

The EMA’s human medicines committee has started a review of Novartis’ sickle cell disease (SCD) therapy Adakveo, shortly after the company reported that it failed to show efficacy in a phase 3 trial. On Friday, Novartis said that the phase 3 STAND trial of Adakveo (crizanlizumab) found no statistically significant difference between the drug and placebo on annualised rates of vaso-occlusive crises (VOCs) – the excruciatingly painful attacks that intermittently affect patients with SC

FDA 52

FDA Hospitals 52